Heart HealthResearch PaperPaywall

Lower LDL After Heart Attack Stenting Linked to Far Less Stent Plaque Regrowth at 3 Years

In a post hoc analysis of 178 STEMI patients with stents, those reaching guideline LDL targets had less neoatherosclerosis on imaging at 3 years.

Thursday, November 19, 2026 1 view
Published in JAMA Cardiol
cardiologist reviewing an intravascular optical coherence tomography image of a coronary stent on a cath lab monitor

Summary

After a heart attack treated with a drug-eluting stent, new fatty plaque can form inside the stent over time. This is called neoatherosclerosis, and it is a major cause of late stent failure. Researchers re-analyzed a randomized trial of 239 STEMI patients and imaged the stents with optical coherence tomography at 3 years in 178 of them. About 55% reached guideline LDL cholesterol targets (average 48 mg/dL) and 45% did not (average 87 mg/dL). Neoatherosclerosis was found in 7% of those at target versus 19% of those not at target. Each 25 mg/dL higher LDL was linked to about 46% higher odds of neoatherosclerosis. This was an association in a post hoc analysis, not a test of a randomized LDL-lowering strategy, so it cannot prove cause. It supports aggressive LDL control after stenting.

Detailed Summary

Stents open blocked arteries after a heart attack, but the vessel wall inside and around the stent can later develop new cholesterol-laden plaque. This process, neoatherosclerosis, is a leading cause of late stent failure and repeat cardiac events. LDL lowering is known to slow plaque progression in native coronary arteries, but its link to plaque formation within stented segments has been unclear.

This was a post hoc analysis of CONNECT, a randomized trial at 7 sites in Switzerland and Japan that compared biodegradable- and durable-polymer everolimus-eluting stents in 239 patients with ST-segment elevation myocardial infarction. Statins were recommended per national guidelines. Optical coherence tomography, an intravascular imaging method, assessed neoatherosclerosis 3 years later in 178 patients (mean age 63.4; 15% female).

Of these, 98 patients (55%) reached guideline LDL targets, averaging 48 mg/dL, while 80 (45%) did not, averaging 87 mg/dL. Neoatherosclerosis occurred in 7% of the target group and 19% of the non-target group. The odds ratio for missing the target was 3.00 (95% CI 1.19-8.24; P=.02). In multivariable logistic regression, each 25 mg/dL increase in on-treatment LDL carried an odds ratio of 1.46 (95% CI 1.09-2.01; P=.01).

The mechanism here is plaque formation within the stented vessel, a structural imaging endpoint rather than a clinical event such as heart attack or death. The findings suggest that the benefit of lower LDL extends to the stented segment, where plaque is a driver of late failure, and they reinforce reaching targets after a heart attack.

Caveats are important. This is a secondary, post hoc analysis, and LDL achievement was not randomized, so confounding such as adherence or baseline risk may play a role. The sample is modest, only 22 patients had the outcome, and the confidence interval is wide. Women were few, and the results are based on the abstract only.

Key Findings

  • Neoatherosclerosis on OCT at 3 years: 7% with LDL at target versus 19% without (OR 3.00, 95% CI 1.19-8.24).
  • Mean on-treatment LDL was 48 mg/dL in the target group versus 87 mg/dL in the non-target group.
  • Each 25 mg/dL higher LDL independently raised neoatherosclerosis odds by 46% (OR 1.46, 95% CI 1.09-2.01).
  • Outcome was an imaging finding, not clinical events; clinical outcomes (death, MI, stent failure) were not reported in the abstract.

Methodology

Post hoc analysis of the randomized CONNECT trial (239 STEMI patients, 7 Swiss and Japanese sites, 2017-2020), with OCT at 3 years in 178 patients. Groups were defined by achievement of guideline LDL targets, and multivariable logistic regression tested LDL as a predictor. LDL achievement was not randomized.

Study Limitations

The summary is based on the abstract only. The analysis is post hoc and non-randomized for LDL, so confounding is possible, the event count is small (22), the confidence intervals are wide, only 15% were women, and imaging was available for 178 of 239 patients. Clinical outcomes were not reported in the abstract.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: